Why Is Alumis Inc. (ALMS) Stock Down -1.61% Today?
Key Takeaways
- ALMS shares slipped about 1.6% in early trading, falling to roughly $7.32 from a prior close of $7.44.
- The decline extends a multi-week slide that began after mixed Phase 2b LUMUS data for its lead drug, envudeucitinib, in systemic lupus erythematosus (SLE).
- A prespecified "IFNGS-high" subgroup showed strong responses, supporting the company's plan to advance into Phase 3 development.
- Analyst reactions have been mixed, with some firms holding Buy ratings while others downgraded or trimmed price targets.
- The next major catalyst is the anticipated NDA submission for envudeucitinib in plaque psoriasis during the fourth quarter of 2026.
Opening Summary
Alumis Inc. (ALMS) is a South San Francisco-based, late-stage biopharmaceutical company developing next-generation oral tyrosine kinase 2 (TYK2) inhibitors for immune-mediated diseases. Its lead candidate, envudeucitinib, is being studied in plaque psoriasis and systemic lupus erythematosus, with a second CNS-penetrant molecule, A-005, in earlier development for neuroinflammatory conditions.
Shares of ALMS were trading lower by about 1.61% on Thursday, around $7.32, compared with a prior session close of $7.44. The move reflects continued selling pressure in a stock that has struggled to find footing since investors reassessed the company's lupus program following a mixed clinical readout earlier this month.
Continued Fallout From the LUMUS Phase 2b Miss
The dominant force behind ALMS' weakness remains the September 1 disclosure of topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe SLE. The study did not meet its primary and secondary endpoints in the overall trial population, triggering an immediate collapse of more than 50% in the share price.
However, the data were not uniformly negative. In a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high), envudeucitinib demonstrated meaningful improvements across multiple measures, including BICLA, CLASI-50, SRI-4, and LLDAS. The drug was generally well tolerated with no new safety signals. Management has argued that the overall miss was driven in part by an under-representation of IFNGS-high patients in the trial, and the company intends to engage regulators on a Phase 3 path that enriches for this biomarker-defined population. Investors, however, have remained cautious, and today's drift reflects lingering skepticism about the lupus program's de-risking rather than any new single headline.
Mixed Analyst Reactions and Price Target Adjustments
Following the LUMUS readout, Wall Street responded with a divided tone that has kept sentiment unsettled. Wells Fargo maintained an Overweight rating but cut its price target sharply, while Oppenheimer held an Outperform rating and lowered its target, describing the post-data selloff as an overreaction given the IFNGS-high subgroup results. Morgan Stanley reiterated a Buy, and HC Wainwright upgraded the stock to Buy, albeit at a lower target. In contrast, Guggenheim downgraded ALMS to Hold, reflecting a more guarded view of the near-term risk profile.
This combination of conflicting calls has contributed to choppy, downward-trending price action. With the consensus view now split between those who see the psoriasis franchise as undervalued and those who view the lupus setback as a meaningful hit to pipeline optionality, the stock has lacked a clear catalyst to reverse its decline.
Market Context and Trading Activity
Trading activity in ALMS has been elevated relative to historical norms over the past two weeks, with multi-million-share sessions recorded as investors repositioned following the clinical data. The stock has shed roughly a quarter of its value over the past two weeks, a decline that stands out against a comparatively steadier backdrop for large-cap biotech.
The move has been driven primarily by company-specific fundamentals rather than broad sector rotation. From a technical standpoint, ALMS has broken below several intermediate support levels during its descent from above $10 in early September to the low-$7 range, with the stock now trading well off its 52-week highs and near the lower end of its recent range. The absence of a meaningful rebound suggests investors remain reluctant to step in ahead of greater clarity on the lupus development path.
What Comes Next for ALMS
The pivotal near-term event for ALMS is the planned submission of a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026, backed by positive Phase 3 ONWARD data. Regulatory feedback on the design of a potential Phase 3 lupus program will also be closely watched, as will any update on the company's cash position and financing plans given its ongoing operating losses.
Risks remain substantial. The lupus program now looks more binary and biomarker-dependent, while the company's clinical-stage status and cash burn leave it exposed to dilution risk if timelines slip. Broader sentiment toward small- and mid-cap biotech, along with sector-wide appetite for high-risk clinical stories, will also influence the stock's path. Investors will be watching for further analyst commentary and any incremental data disclosures in the weeks ahead.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots, drawn from hundreds of strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to explore systematic approaches matched to today's market environment. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
ALMS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALMS turned positive on September 22, 2026. Looking at past instances where ALMS's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in 100 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
ALMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALMS as a result. In 33 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ALMS entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.050) is normal, around the industry mean (26.782). P/E Ratio (0.166) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (123.457) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. ALMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement